CD8A and prostate carcinoma: A study revealed that EVs derived from prostate cancer cells containing prostaglandin E+2 could enhance the expression of the CD73 molecule on the surface of DCs, inhibiting the cross-presentation of tumor-associated antigens by DCs and impairing the activation of CD8+ T cells (93).